Edgewise Therapeutics, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Edgewise Therapeutics, Inc. (EWTX) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$2.47 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-06
- Edgewise Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $579.00K, a 76.58% decline year-over-year.
- Edgewise Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$3.04M, a 306.02% decline year-over-year.
- Edgewise Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $2.71M.
- Edgewise Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $1.30M.
- Edgewise Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $7.96M.
- Edgewise Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$3.29M, a 192.65% decline from fiscal 2023.
- Edgewise Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $3.55M, a 144.70% increase from fiscal 2022.
- Edgewise Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $1.45M, a 39.30% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $579.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$2.47M 10-Q · filed 2026-08-06 | $249.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.55M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$3.04M 10-Q · filed 2026-05-07 | -$330.00K derived: sum of 2 quarters · filed 2026-05-07 | $968.00K derived: sum of 3 quarters · filed 2026-05-07 | $3.44M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.01M derived: sum of 2 quarters · filed 2026-02-26 | $6.49M derived: sum of 3 quarters · filed 2026-08-06 | $7.96M 10-K · filed 2026-02-26 |
| 2025-09-30 | $1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.77M derived: sum of 2 quarters · filed 2026-08-06 | $5.25M 10-Q · filed 2025-11-06 | $3.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $3.95M 10-Q · filed 2026-08-06 | $2.36M derived: sum of 3 quarters · filed 2026-08-06 | $1.57M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.48M 10-Q · filed 2026-05-07 | -$109.00K derived: sum of 2 quarters · filed 2026-05-07 | -$900.00K derived: sum of 3 quarters · filed 2026-05-07 | -$1.88M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$1.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$2.38M derived: sum of 2 quarters · filed 2026-02-26 | -$3.35M derived: sum of 3 quarters · filed 2026-02-26 | -$3.29M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$791.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.77M derived: sum of 2 quarters · filed 2025-11-06 | -$1.71M 10-Q · filed 2025-11-06 | -$1.33M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$977.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$914.00K 10-Q · filed 2025-08-07 | -$535.00K derived: sum of 3 quarters · filed 2026-02-26 | $622.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $63.00K 10-Q · filed 2025-05-08 | $442.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.60M derived: sum of 3 quarters · filed 2026-02-26 | $3.26M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $379.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.54M derived: sum of 2 quarters · filed 2026-02-26 | $3.19M derived: sum of 3 quarters · filed 2026-02-26 | $3.55M 10-K · filed 2026-02-26 |
| 2023-09-30 | $1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $2.81M derived: sum of 2 quarters · filed 2024-11-07 | $3.17M 10-Q · filed 2024-11-07 | $2.90M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $1.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $2.02M 10-Q · filed 2024-08-08 | $1.74M derived: sum of 3 quarters · filed 2024-08-08 | $1.93M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $359.00K 10-Q · filed 2024-05-09 | $80.00K derived: sum of 2 quarters · filed 2024-05-09 | $270.00K derived: sum of 3 quarters · filed 2024-05-09 | $2.21M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$279.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$89.00K derived: sum of 2 quarters · filed 2024-02-22 | $1.85M derived: sum of 3 quarters · filed 2024-02-22 | $1.45M 10-K · filed 2024-02-22 |
| 2022-09-30 | $190.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $2.13M derived: sum of 2 quarters · filed 2023-11-09 | $1.73M 10-Q · filed 2023-11-09 | $2.17M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $1.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $1.54M 10-Q · filed 2023-08-10 | $1.98M derived: sum of 3 quarters · filed 2023-08-10 | $922.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$398.00K 10-Q · filed 2023-05-11 | $43.00K derived: sum of 2 quarters · filed 2023-05-11 | -$1.02M derived: sum of 3 quarters · filed 2023-05-11 | $1.93M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $441.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$619.00K derived: sum of 2 quarters · filed 2023-02-23 | $2.33M derived: sum of 3 quarters · filed 2023-02-23 | $2.39M 10-K · filed 2023-02-23 |
| 2021-09-30 | -$1.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $1.89M derived: sum of 2 quarters · filed 2022-11-03 | $1.95M 10-Q · filed 2022-11-03 | $1.99M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $2.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $3.01M 10-Q · filed 2022-08-04 | $3.04M derived: sum of 3 quarters · filed 2022-08-04 | $3.35M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $66.00K 10-Q · filed 2022-05-11 | $100.00K derived: sum of 2 quarters · filed 2022-05-11 | $404.00K derived: sum of 3 quarters · filed 2022-05-11 | $442.00K derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $34.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $338.00K derived: sum of 2 quarters · filed 2022-02-24 | $376.00K derived: sum of 3 quarters · filed 2022-02-24 | $417.00K 10-K · filed 2022-02-24 |
| 2020-09-30 | $304.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $342.00K derived: sum of 2 quarters · filed 2021-11-10 | $383.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $38.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $79.00K 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $41.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |